🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Deep Learning on Amyloid Positons Emission Tomography

Recruitingn/aAges 18 Years - 99 YearsAllCentral Hospital, Nancy, France
NCT07309107 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Reducing injected dose and/or acquisition time in amyloid PET imaging would improve comfort, radiation safety and cost-effectiveness in diagnosis and follow-up of patients. This study evaluates the impact of a deep learning-based noise reduction algorithm on visual analysis and Centiloid quantification when simulating reduced injected doses of \[18F\]flutemetamol.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with objective cognitive impairment, * Referred to our department for a cerebral \[¹⁸F\]flutemetamol positron emission tomography scan between January 1, 2023 and July 1, 2025, Exclusion Criteria: * Patient have objected to the use of their data.
💊

What it tests

  • Not listed
📍

Where

3 sites
CHRU NANCY Brabois, nuclear medicine department
Vandœuvre-lès-Nancy, France
Nancy's hospital
Vandœuvre-lès-Nancy, France
Nuclear medicine department CHRU de NANCY Brabois
Vandœuvre-lès-Nancy, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy